The Latest Cardiac and Vascular News
WAKEFIELD, Mass., April 12, 2023 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the completion of patient enrollment in the TARGET BP I Pivotal Study evaluating alcohol-mediated renal denervation with the Peregrine System. “We are pleased to announce this significant milestone”, stated Kate Rumrill, […]
WAKEFIELD, Mass., June 13, 2022 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the completion of the fourth tranche of its Series D financing round, resulting in $91.4 million in aggregate proceeds to the Company from the Series D financing round. Gilde Healthcare, BioStar Capital, Invus […]
Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif., Feb. 20, 2020 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market Study demonstrating the safety and efficacy of the company’s CE-marked […]
SAN JOSE, Calif.–(BUSINESS WIRE)–Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and CEO. Rumrill will also serve on the board of directors for the company. With 30 years industry experience, Rumrill brings deep […]
KALAMAZOO, Mich.–(BUSINESS WIRE)–Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate […]
